Successful Treatment of Recurrent Clostridioides difficile Infection Using a Novel, Drinkable, Oral Formulation of Fecal Microbiota.
Fecal microbiota transplantation (FMT)
Organoleptic
Pediatric patients
Recurrent Clostridioides difficile infection
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
30
09
2023
accepted:
09
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
Fecal microbiota transplants can be administered orally in encapsulated form or require invasive procedures to administer liquid formulations. There is a need for an oral liquid formulation of fecal microbiota for patients who are unable to swallow capsules, especially if they require multiple, repeated administrations. These studies were conducted to develop a protocol to manufacture an organoleptically acceptable powdered fecal microbiota formulation that can be suspended in a liquid carrier and used for fecal microbiota transplantation. Several processing steps were investigated, including extra washes of microbiota prior to lyophilization and an addition of a flavoring agent. The viability of bacteria in the transplant formulation was tested using live/dead microscopy staining and engraftment into antibiotic-treated mice. After development of a clinical protocol for suspension of the powdered microbiota, the new formulation was tested in three elderly patients with recurrent Clostridioides difficile infections and who have difficulties in swallowing capsules. Changes in the microbial community structure in one of the patients were characterized using 16S rRNA gene profiling and engraftment analysis. The processing steps used to produce an organoleptically acceptable suspension of powdered fecal microbiota did not result in loss of its viability. The powder could be easily suspended in a liquid carrier. The use of the new formulation was associated with abrogation of the cycle of C. difficile infection recurrences in the three patients. We developed a novel organoleptically acceptable liquid formulation of fecal microbiota that is suitable for use in clinical trials for patients with difficulties in swallowing capsules.
Sections du résumé
BACKGROUND
BACKGROUND
Fecal microbiota transplants can be administered orally in encapsulated form or require invasive procedures to administer liquid formulations. There is a need for an oral liquid formulation of fecal microbiota for patients who are unable to swallow capsules, especially if they require multiple, repeated administrations.
AIMS
OBJECTIVE
These studies were conducted to develop a protocol to manufacture an organoleptically acceptable powdered fecal microbiota formulation that can be suspended in a liquid carrier and used for fecal microbiota transplantation.
METHODS
METHODS
Several processing steps were investigated, including extra washes of microbiota prior to lyophilization and an addition of a flavoring agent. The viability of bacteria in the transplant formulation was tested using live/dead microscopy staining and engraftment into antibiotic-treated mice. After development of a clinical protocol for suspension of the powdered microbiota, the new formulation was tested in three elderly patients with recurrent Clostridioides difficile infections and who have difficulties in swallowing capsules. Changes in the microbial community structure in one of the patients were characterized using 16S rRNA gene profiling and engraftment analysis.
RESULTS
RESULTS
The processing steps used to produce an organoleptically acceptable suspension of powdered fecal microbiota did not result in loss of its viability. The powder could be easily suspended in a liquid carrier. The use of the new formulation was associated with abrogation of the cycle of C. difficile infection recurrences in the three patients.
CONCLUSION
CONCLUSIONS
We developed a novel organoleptically acceptable liquid formulation of fecal microbiota that is suitable for use in clinical trials for patients with difficulties in swallowing capsules.
Identifiants
pubmed: 38457115
doi: 10.1007/s10620-024-08351-7
pii: 10.1007/s10620-024-08351-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78:240–249.
doi: 10.1016/j.gie.2013.03.1329
pubmed: 23642791
Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect. 2003;36:580–585.
doi: 10.1086/367657
Hamilton MJ, Weingarden AR, Sadowsky MJ et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–767.
doi: 10.1038/ajg.2011.482
pubmed: 22290405
Staley C, Hamilton MJ, Vaughn BP et al. Successful resolution of recurrent clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017;112:940–947.
doi: 10.1038/ajg.2017.6
pubmed: 28195180
pmcid: 5552199
Vaughn BP, Fischer M, Kelly CR et al. Effectiveness and safety of colonic and capsule fecal microbiota transplantation for recurrent Clostridioides difficile infection. Clin Gastroenterol Hepatol. 2022;21:1330.
doi: 10.1016/j.cgh.2022.09.008
pubmed: 36126907
Kang DW, Adams JB, Gregory AC et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5:10.
doi: 10.1186/s40168-016-0225-7
pubmed: 28122648
pmcid: 5264285
Haifer C, Paramsothy S, Kaakoush NO et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022;7:141–151.
doi: 10.1016/S2468-1253(21)00400-3
pubmed: 34863330
Staley C, Kaiser T, Beura LK et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. Microbiome. 2017;5:87.
doi: 10.1186/s40168-017-0306-2
pubmed: 28760163
pmcid: 5537947
Caporaso JG, Lauber CL, Walters WA et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012;6:1621–1624.
doi: 10.1038/ismej.2012.8
pubmed: 22402401
pmcid: 3400413
Gohl DM, Vangay P, Garbe J et al. Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies. Nat Biotechnol. 2016;34:942–949.
doi: 10.1038/nbt.3601
pubmed: 27454739
Schloss PD, Westcott SL, Ryabin T et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75:7537–7541.
doi: 10.1128/AEM.01541-09
pubmed: 19801464
pmcid: 2786419
Staley C, Kaiser T, Vaughn BP et al. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome. 2018;6:166.
doi: 10.1186/s40168-018-0549-6
pubmed: 30227892
pmcid: 6145197
Pruesse E, Quast C, Knittel K et al. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 2007;35:7188–7196.
doi: 10.1093/nar/gkm864
pubmed: 17947321
pmcid: 2175337
Edgar RC, Haas BJ, Clemente JC et al. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011;27:2194–2200.
doi: 10.1093/bioinformatics/btr381
pubmed: 21700674
pmcid: 3150044
Cole JR, Wang Q, Cardenas E et al. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009;37:D141-145.
doi: 10.1093/nar/gkn879
pubmed: 19004872
Knights D, Kuczynski J, Charlson ES et al. Bayesian community-wide culture-independent microbial source tracking. Nat Methods. 2011;8:761–763.
doi: 10.1038/nmeth.1650
pubmed: 21765408
pmcid: 3791591
Dettmar PW, Strugala V, Fisher J et al. Antacid efficacy of maalox in comparison to a range of antacids. J Pharm Sci Therap. 2019;5:301–325.
Martinez-Guryn K, Hubert N, Frazier K et al. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe. 2018;23:458-469.e455.
doi: 10.1016/j.chom.2018.03.011
pubmed: 29649441
pmcid: 5912695
de Vos P, Mujagic Z, de Haan BJ et al. Strains can enhance human mucosal and systemic immunity and prevent non-steroidal anti-inflammatory drug induced reduction in T regulatory. Cells Front Immunol. 2017;8:1000.
doi: 10.3389/fimmu.2017.01000
pubmed: 28878772
Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol. 2021;18:67–80.
doi: 10.1038/s41575-020-0350-4
pubmed: 32843743